The survey is part of a pre-marketing campaign of PURA’s new CBD Infused beer, coffee and tea beverages.
DALLAS, Sept. 13, 2019 (GLOBE NEWSWIRE) — via OTC PR WIRE – Puration, Inc. (USOTC: PURA) (”PURA”) today announced that the company expects to publish results from the previously announced CBD infused beverage market survey next week. The survey is being conducted by Goldman Small Cap Research.
The survey is part of a pre-marketing campaign of PURA’s new CBD Infused beer, coffee and tea beverages. The data collected will be used to target PURA’s marketing direction for CBD infused beer, coffee and tea.
PURA recently implemented a program to introduce CBD infused versions of existing third-party beverages.
The company has announced plans to introduce a CBD infused beer in partnership with an existing beer producer and in similar fashion, PURA has partnered with an existing coffee producer and tea producer to introduce CBD infused coffee and tea. The company recently published a presentation on its beer, coffee and tea initiative that is included in its entirety on the company’s website.
PURA is already a leading CBD infused beverage company having produced over $1 million in CBD Beverages in the United States last year (2018) and reporting over $1 million in CBD Beverages for just the first six months of 2019.
PURA has targeted $4 million in sales for 2019.Look for news next week on the company’s rollout of its EVERx CBD Sports Water marketing campaign in Europe kicking off at Arnold Schwarzenegger’s Arnold Sports Festival Europe in Barcelona September 20-22, 2019. EVERx CBD Sports Water is available already in Europe through select distributors. With the EVERx CBD Sports Water campaign starting next week, PURA plans to expand its European sales. EVERx CBD Sports Water is available for purchase on line at www.USMJ.com hosted by PURA’s partner North American Cannabis Holdings, Inc. (USOTC: USMJ).For more information on Puration, visit http://www.purationinc.com
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.